Sign in
Taking people in United StatesEarly phase 1

Testing trehalose and small blood vessel function in adults with type 2 diabetes

Tests trehalose, compared with placebo, on small blood vessels in adults with diabetes.

Key facts

Who runs it
Medical College of Wisconsin
Where
Milwaukee, United StatesSee the site
Trial code
Registry title
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
Status
Recruiting
Phase
Early phase 1
People taking part
60 people, planned
Started
1 Jan 2023
Expected to end
31 Dec 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Trehalose
  • Placebo
Record updated
30 October 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Type 2 Diabetes and otherwise healthy adults with no more than 1 cardiovascular risk factor. It studies how autophagy affects the function of small blood vessels.

Age
18 to 80 years
Sex
All sexes can join.
Disease stage
Type 2 Diabetes diagnosed in line with American Diabetes Association (ADA) guidelines, or otherwise healthy people with no more than 1 cardiovascular risk factor.
Earlier treatment
People cannot join if they used anti-coagulant or anti-platelet drugs, hormone replacement therapy, or steroids in the last 6 months. Anti-cancer treatment in the last 12 months also rules people out.

Main reasons for not taking part

  • Type 1 Diabetes
  • Current tobacco use or use within the last 6 months
  • BMI above 35
  • Uncontrolled hypertension, symptomatic coronary artery disease, or heart failure
  • Active COVID-19 or COVID-19 within the past 3 months

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Clinical Diagnosis of Type 2 Diabetes Mellitus in accordance with American Diabetes Association (ADA) guidelines (Type 2 Diabetic group)
  • Otherwise healthy individuals (Healthy control group) with no more than 1 cardiovascular risk factor

Who cannot take part

  • Hormone Replacement Therapy
  • Use Erectile Dysfunction Medication in the past 6 months
  • Use of Topical/non-topical Steroids in last 6 months
  • Gender Reassignment Therapy
  • Uncontrolled hypertension
  • Type 1 Diabetes
  • Symptomatic coronary artery disease
  • Heart Failure
  • Renal Impairment
  • History of Retinopathy
  • Documented Neuromuscular Disorders
  • Allergies to Povidone Iodine
  • Active Anti-Cancer Treatment or Treatment within last 12 months
  • Active COVID-19 or within the past 3 months
  • Use of anti-coagulant drugs, or anti-platelet drugs
  • Current Tobacco use or within last 6 months
  • BMI > 35
  • Hyperlipidemia
  • Hypercholesterolemia
  • Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity)
  • Pregnancy (Young Female subjects)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • Medical College of WisconsinMilwaukee, United StatesContact: William Hughes, Ph.D.Taking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to examine the role of autophagy on microvascular function in adults with Type 2 Diabetes. The main question it aims to answer are:

Read full original descriptionShow less

* Does presence of Type 2 Diabetes reduce autophagy and impair microvascular function? * Does exposure to high glucose impair autophagy and subsequently microvascular function?

Participants will undergo 2 study days. The primary outcome will be in vivo microvascular function testing. Following the first study day participants will undergo either supplementation with trehalose, an autophagy activator, or placebo for 14 days. The second study day will test in vivo microvascular function.

The 2 groups in the trial

  • TrehaloseTreatment being tested

    10g mixed in 500 mL of water, consumed 1 time per day

  • PlaceboPlacebo, for comparison

    10g microcrystalline cellulose in 500 mL, consumed 1 time per day

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
Plain-language title
Testing trehalose and small blood vessel function in adults with type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05593549, who can take part
Record updated
30 October 2025